Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients

Trial Profile

Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Feb 2018 Results of a pooled analysis of NCT02918357 & NCT02611882 (n=158) in detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy, presented at the 2018 Genitourinary Cancers Symposium
    • 16 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top